Bon Secours Mercy Health, a nonprofit Catholic health system, said Monday it intends to acquire Surgery Partners, a publicly traded chain that operates more than 200 ambulatory surgery centers, short-stay hospitals, and multispecialty physician practices in 30 states. The transaction is valued at $5.7 billion and is expected to close in the first quarter of 2027, according to the announcement.
The deal would position Bon Secours Mercy Health among the largest operators of outpatient surgery facilities in the United States and would deepen the health system’s existing relationship with private equity firm Bain Capital, which is tied to Surgery Partners’ ownership.
Hospital operators of all types have been buying ambulatory surgery centers (ASCs) at a brisk pace in recent years. Industry observers and the reporting in the source note several drivers behind that trend:
By acquiring Surgery Partners, Bon Secours Mercy Health could boost its profitability and increase its negotiating leverage with health insurers, the reporting said. The source did not provide specific projected financial impacts, expected cost savings, or details about how the system plans to integrate Surgery Partners’ operations.
Surgery Partners operates a mix of ambulatory surgery centers, short-stay hospitals, and physician practice groups across 30 states. The company’s network exceeds 200 sites, a scale that would substantially expand Bon Secours Mercy Health’s outpatient surgery capacity if the deal closes as planned.
The announcement linked the transaction to Bain Capital, indicating that the acquisition will deepen ties between the nonprofit system and the private equity firm. The source did not disclose the ownership breakdown, transaction structure, or financing details beyond the headline purchase price.
The purchase of Surgery Partners is part of a broader consolidation trend among hospital systems and investors. The source points to a comparable deal earlier in 2026: nonprofit Ascension paid $3.9 billion for Amsurg, which expanded that system’s network of ambulatory surgery centers to roughly 300 sites.
These transactions reflect a strategic bet by hospital systems that expanding outpatient capabilities will capture volume and revenue as more procedures migrate away from inpatient settings. The source did not include independent analysis of market concentration, regional impacts, or expected effects on patient access or prices.
According to the reporting, the acquisition could strengthen Bon Secours Mercy Health’s market position and financial performance. At the same time, several practical and regulatory questions remain unanswered in the source material:
Those are typical issues in major health-system acquisitions, but the source did not supply additional specifics.
Bon Secours Mercy Health said it plans to complete the transaction in the first quarter of 2027. Between now and closing, standard steps for deals of this size would typically include due diligence, financing arrangements, and any required regulatory reviews. The source did not describe the timeline or milestones that must be met before the acquisition is finalized.
Observers will likely watch for how the merged organization positions its outpatient network, how payers respond, and whether the deal spurs further consolidation among hospital systems seeking scale in ambulatory services. The source did not report comments from payers, regulators, or patient advocates.
This coverage is based on the announcement reported by the source on Oct. 26, 2026. The author of the original piece is Tara Bannow, Hospitals and Insurance Reporter. The facts in this report are drawn from that announcement and the source’s contextual reporting. Where the source did not provide further information — for example, on deal financing, regulatory reviews, or integration plans — those specifics are noted as not reported.
If completed, the $5.7 billion acquisition of Surgery Partners would significantly expand Bon Secours Mercy Health’s ambulatory surgery footprint and align the nonprofit more closely with private equity interests via Bain Capital. The transaction arrives amid a broader industry shift toward outpatient care and follows other large ASC purchases, including Ascension’s $3.9 billion buy of Amsurg earlier in 2026. The full implications for competition, prices, and patient care will depend on details the source did not report and on developments during the remaining deal process.
Personalise this feed
Your specialty. Your sources. Your digest.
All set up in under 2 minutes.
Personalise this feed
Your specialty. Your sources. Your digest.
All set up in under 2 minutes.